secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001558370-24-010321
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed
--------------------------------------------------------------------------------

- Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.
- MThera may conduct a Phase 3 trial in the U.S. and South Korea; NeuroBo to focus on DA-1726 and DA-1241.
- Phase 2 efficacy data cited by MThera; financial terms not disclosed.
- NeuroBo CEO says deal reflects commitment to out-license legacy assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/0001558370-24-010321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/nrbo-20240730x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer